Kaya Limited: SEBI Takeover Disclosure under Regulation 31(4)
Kaya Limited, a multi-specialty healthcare and aesthetic services operator, submitted a disclosure of substantial acquisition to NSE on 30 June 2026 under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing indicates a shareholder acquisition event meeting the 5% disclosure threshold. The acquirer identity, consideration, and final shareholding percentage are not disclosed in the regulatory notice itself; these details are contained in the full Form DIS-4 filed with the exchange.
Why it mattersRegulation 31(4) disclosure is triggered upon acquisition of 5% or more shares, requiring the acquirer to make open-market purchases transparent; this filing confirms the transaction crossed the statutory threshold for takeover code applicability and competitor/shareholder access under SEBI rules.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives - Kaya Limited Takeover Disclosure · official
- SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026